Efficacy and safety of bendamustine‐containing bridging therapy in R/R LBCL patients receiving CD19 CAR T‐cells

Abstract Bridging therapy (BT) after leukapheresis is required in most relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) patients receiving chimeric antigen receptor (CAR) T cells. Bendamustine‐containing regimens are a potential BT option. We aimed to assess if this agent had a negative impact...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Gloria Iacoboni, Mario A. Sánchez‐Salinas, Kai Rejeski, Ana Á. Martín‐López, Mi Kwon, Víctor Navarro, Katarzyna A. Jalowiec, Rafael Hernani, Juan L. Reguera‐Ortega, Laura Gallur, Viktoria Blumenberg, María Herrero‐García, Claire Roddie, Ana Benzaquén, Javier Delgado‐Serrano, Rebeca Bailén, Cecilia Carpio, Paula Amat, Lucia López‐Corral, Lourdes Martín‐Martín, Mariana Bastos, Marion Subklewe, Maeve O'Reilly, Pere Barba
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2024-07-01
Rangatū:	HemaSphere
Urunga tuihono:	https://doi.org/10.1002/hem3.86
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!